USPTO serial 79437611
TARGED TARGETED ENZYME DELIVERY
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 30, 2026
- Examiner
- HUDSON, TAMARA BREE
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with TARGED TARGETED ENZYME DELIVERY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Lindsay M.R. Jones
P.O. Box 2910Minneapolis, MN 55402United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of diseases associated with thrombosis; medical preparations for the treatment of diseases associated with thrombosis; dietary supplements for medical purposes; medicinal herbs and medicinal herbal extracts; drugs for medical purposes for the treatment of diseases associated with thrombosis, pharmaceutical preparations for the prevention and treatment of diseases associated with thrombosis; pharmaceutical preparations being antithrombotic agents; thrombolytic drugs; pharmaceutical preparations being coagulation inhibitors; anticoagulants; pharmaceutical preparations in the nature of platelet aggregation inhibitors; pharmaceutical preparations in the nature of hemostatic agents; pharmaceutical preparations, namely, blood thinners for medical use; therapeutic compounds for diseases associated with thrombosis; pharmaceutical preparations for cardiovascular diseases; pharmaceutical preparations for blood clotting disorders; injectable or intravenous medicinal solutions for thrombosis-related treatment; medicinal preparations for the treatment of deep vein thrombosis (DVT); medicinal preparations for pulmonary embolism (PE) management; preclinical or clinical trial medicines for thrombosis-related treatment research; pharmaceuticals for vascular diseases | ACTIVE | — |
| 042 | Scientific and technological services, namely, research and design in the field of medicine and pharmaceuticals; research and development services in the field of medicine and pharmaceuticals; scientific research in the nature of conducting laboratory and clinical testing for others; biotechnology research services; pharmaceutical research services; medical and scientific laboratory services; medical research and development services; research and development in the field of thrombosis treatment; pharmaceutical and biotechnology research for antithrombotic drugs; scientific research in the nature of conducting preclinical and clinical trials for others in the field of drugs for diseases associated with thrombosis; d r u g discovery services related to thrombosis; development of biopharmaceuticals for cardiovascular diseases; scientific research in the field of platelet aggregation inhibitors; consultancy services in pharmaceutical research and development; conducting scientific studies related to thrombosis-related and blood clotting disorders; scientific research in the nature of conducting clinical trials for others in the field of thrombosis-related drugs and therapies; design and development of drug efficacy studies for treatment of diseases associated with thrombosis; genetic research and molecular biology research services related to thrombosis; technical data analysis of scientific research and providing temporary use of online, non-downloadable computer software for use in modeling in the field of treatment of diseases associated with thrombosis; laboratory research services for thrombosis-related diagnosis and testing; research services related to anticoagulation therapy; research in personalized medicine for patients of diseases associated with thrombosis patients; quality assessment, namely, reference material certification services being the testing, analysis and evaluation of the goods of others to determine conformity with certification standards in the field of treatment of diseases associated with thrombosis treatment; research and development services for biotechnological solutions for diseases associated with thrombosis; scientific advisory and consultation services in thrombosis-related research | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by TargED Biopharmaceuticals B.V.
- Other trademarks owned by TargED Biopharmaceuticals B.V.
- Other trademarks owned by TargED Biopharmaceuticals B.V.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named TARGED TARGETED ENZYME DELIVERY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 30, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jun 30, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jun 30, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 12, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 12, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 6, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 14, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 14, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 14, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Apr 14, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 14, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 14, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 14, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 14, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 26, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 12, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 11, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 15, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 14, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 7, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 28, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 28, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 27, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |